

# VET01

## Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

This standard covers the current recommended methods for disk diffusion susceptibility testing and the reference methods for determining minimal inhibitory concentrations of aerobic bacteria by broth macrodilution, broth microdilution, and agar dilution for veterinary use.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

This is a preview. [Click here to purchase the full publication.](#)

---

# Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

Michael T. Sweeney, MS  
Dubraska V. Diaz-Campos, DVM, PhD  
Robert Bowden, BS  
Thomas R. Fritsche, MD, PhD, FCAP, FIDSA  
Joshua Hayes, PhD  
Cory Langston, DVM, PhD  
Brian V. Lubbers, DVM, PhD, DACVCP

Tomás Martin-Jimenez, DVM, PhD, DACVCP,  
DECVPT  
Claire Miller, DVM, PhD, DACVM  
Christine Pallotta, MS, BS  
Mark G. Papich, DVM, MS  
Anne Parkinson, BS  
Stefan Schwarz, DVM  
Maria M. Traczewski, BS, MT(ASCP)

## Abstract

Antimicrobial susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy if its susceptibility cannot be reliably predicted from knowledge of the organism's identity. Susceptibility tests are most often indicated when the causative organism is thought to belong to a species capable of exhibiting resistance to commonly used antimicrobial agents.

Various laboratory methods can be used to measure the *in vitro* susceptibility of bacteria to antimicrobial agents. In many veterinary microbiology laboratories, an agar disk diffusion method is used routinely for testing common, rapidly growing, and certain fastidious bacterial pathogens. Clinical and Laboratory Standards Institute standard VET01—*Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals* describes disk diffusion, as well as standard broth dilution (macrodilution and microdilution) and agar dilution, and it includes a series of procedures to standardize the way the tests are performed. The performance, applications, and limitations of the current CLSI-recommended methods are also described. The supplemental information (VET08<sup>1</sup> tables) used with this standard represents the most current information for antimicrobial agent selection, interpretation, and quality control using the procedures standardized in VET01.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals*. 5th ed. CLSI standard VET01 (ISBN 978-1-68440-008-9 [Print]; ISBN 978-1-68440-009-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2018.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



Copyright ©2018 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals*. 5th ed. CLSI standard VET01. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

### **Previous Editions:**

August 1997, June 1999, May 2002, February 2008, July 2013

ISBN 978-1-68440-008-9 (Print)  
ISBN 978-1-68440-009-6 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

Volume 38, Number 13

## Committee Membership

### Consensus Council

**Dennis J. Ernst, MT(ASCP),  
NCPT(NCCT)  
Chairholder  
Center for Phlebotomy Education  
USA**

**Mary Lou Gantzer, PhD, FACB  
Vice-Chairholder  
USA**

J. Rex Astles, PhD, FACB, DABCC  
Centers for Disease Control and  
Prevention  
USA

Lucia M. Berte, MA, MT(ASCP)SBB,  
DLM, CQA(ASQ)CMQ/OE  
Laboratories Made Better!  
USA

Karen W. Dyer, MT(ASCP), DLM  
Centers for Medicare & Medicaid  
Services  
USA

Thomas R. Fritsche, MD, PhD, FCAP,  
FIDSA  
Marshfield Clinic  
USA

Loralie J. Langman, PhD, DABCC,  
FACB, F-ABFT  
Mayo Clinic  
USA

Ross J. Molinaro, PhD,  
MLS(ASCP)CM, DABCC, FACB  
Siemens Healthcare Diagnostics, Inc.  
USA

James R. Petisce, PhD  
BD Diagnostic Systems  
USA

Andrew Quintenz  
Bio-Rad Laboratories, Inc.  
USA

Robert Rej, PhD  
New York State Department of Health –  
Wadsworth Center  
USA

Zivana Tezak, PhD  
FDA Center for Devices and  
Radiological Health  
USA

### Document Development Committee on Veterinary AST Methods Standard

**Michael T. Sweeney, MS  
Zoetis  
Chairholder  
USA**

**Dubrasca V. Diaz-Campos,  
DVM, PhD  
Vice-Chairholder  
College of Veterinary Medicine,  
The Ohio State University  
USA**

**Maria M. Traczewski, BS, MT(ASCP)  
Committee Secretary  
The Clinical Microbiology Institute  
USA**

Robert Bowden, BS  
University of Florida Veterinary  
Diagnostic Laboratories  
USA

Joshua Hayes, PhD  
FDA Center for Veterinary Medicine  
USA

Cory Langston, DVM, PhD  
Mississippi State University  
USA

Claire Miller, DVM, PhD, DACVM  
Washington State University  
USA

Christine Pallotta, MS, BS  
Thermo Fisher Scientific  
USA

Anne Parkinson, BS  
Ohio Animal Disease Diagnostic  
Laboratory  
USA

Stefan Schwarz, DVM  
Freie Universität Berlin  
Germany

## Subcommittee on Veterinary Antimicrobial Susceptibility Testing

**Mark G. Papich, DVM, MS**  
**Chairholder**  
**College of Veterinary Medicine,**  
**North Carolina State University**  
**USA**

**Brian V. Lubbers, DVM, PhD,**  
**DACVCP**  
**Vice-Chairholder**  
**Kansas State Veterinary Diagnostic**  
**Laboratory**  
**USA**

**Stefan Schwarz, DVM**  
**Committee Secretary**  
**Freie Universität Berlin**  
**Germany**

Dubrasca V. Diaz-Campos, DVM, PhD  
 College of Veterinary Medicine,  
 The Ohio State University  
 USA

### Staff

Clinical and Laboratory Standards  
 Institute  
 USA

Lori T. Moon, MS, MT(ASCP)  
*Project Manager*

Mark Fielder, PhD  
 School of Life Science,  
 Kingston University London  
 United Kingdom

Cynthia C. Knapp, MS, BS, MT(ASCP)  
 Thermo Fisher Scientific  
 USA

Cory Langston, DVM, PhD  
 Mississippi State University  
 USA

Xian-Zhi Li, PhD  
 Health Canada Veterinary Drugs  
 Directorate  
 Canada

Marilyn N. Martinez, PhD  
 FDA Center for Veterinary Medicine  
 USA

Thomas R. Shryock, PhD  
 Antimicrobial Consultants, LLC  
 USA

Virginia Sinnott-Stutzman, DVM,  
 DACVECC  
 Angell Animal Medical Center  
 (MSPCA)  
 USA

Maria M. Traczewski, BS, MT(ASCP)  
 The Clinical Microbiology Institute  
 USA

Darren Trott, BSc(Hon), BVMS(Hon),  
 PhD  
 School of Animal and Veterinary  
 Sciences, The University of Adelaide  
 Australia

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Catherine E.M. Jenkins  
*Editor*

Kristy L. Leirer, MS  
*Editor*

Laura Martin  
*Editor*

## Acknowledgment for the Expert Panel on Microbiology

CLSI, the Consensus Council, the Document Development Committee on Veterinary AST Methods Standard, and the Subcommittee on Veterinary Antimicrobial Susceptibility Testing gratefully acknowledge the Expert Panel on Microbiology for serving as technical advisors and subject matter experts during the development of this standard.

## Expert Panel on Microbiology

**Richard B. Thomson, Jr., PhD,**  
**D(ABMM), FAAM**  
**Chairholder**  
**Evanston Hospital, NorthShore**  
**University HealthSystem**  
**USA**

**Mary Jane Ferraro, PhD, MPH**  
**Vice-Chairholder**  
**Massachusetts General Hospital and**  
**Harvard Medical School**  
**USA**

Lynette Y. Berkeley, PhD, MT(ASCP)  
 FDA Center for Drug Evaluation and  
 Research  
 USA

Carey-Ann Burnham, PhD, D(ABMM)  
 Washington University School of  
 Medicine  
 USA

German Esparza, BSc  
 Proasecal SAS  
 Colombia

Mark G. Papich, DVM, MS  
 College of Veterinary Medicine,  
 North Carolina State University  
 USA

Jean B. Patel, PhD, D(ABMM)  
 Centers for Disease Control and  
 Prevention  
 USA

David H. Pincus, MS, RM/SM(NRCM),  
 SM(ASCP)  
 bioMérieux, Inc.  
 USA

Audrey N. Schuetz, MD, MPH,  
 D(ABMM)  
 Mayo Clinic  
 USA

Ribhi M. Shawar, PhD, D(ABMM)  
 FDA Center for Devices and  
 Radiological Health  
 USA

Barbara L. Zimmer, PhD  
 Beckman Coulter – West Sacramento  
 USA

## Acknowledgment

CLSI, the Consensus Council, the Document Development Committee on Veterinary AST Methods Standard, and the Subcommittee on Veterinary Antimicrobial Susceptibility Testing gratefully acknowledge the following volunteers for their important contributions to the development of this standard:

Thomas R. Fritsche, MD, PhD, FCAP, FIDSA  
Marshfield Clinic  
USA

Brian V. Lubbers, DVM, PhD, DACVCP  
Kansas State Veterinary Diagnostic Laboratory  
USA

Tomás Martín-Jiménez, DVM, PhD, DACVCP, DECVPT  
College of Veterinary Medicine, University of Tennessee  
USA

Mark G. Papich, DVM, MS  
College of Veterinary Medicine,  
North Carolina State University  
USA





## Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	ix
Chapter 1: Introduction.....	1
1.1 Scope.....	1
1.2 Background.....	2
1.3 Standard Precautions.....	5
1.4 Terminology.....	5
Chapter 2: Indications for Performing Antimicrobial Susceptibility Tests.....	9
2.1 Selecting Antimicrobial Agents for Routine Testing.....	10
2.2 Antimicrobial Agent Classes .....	11
2.3 Guidelines for Routine Reporting .....	14
2.4 Guidelines for Selective Reporting.....	15
Chapter 3: Overview of Antimicrobial Susceptibility Testing Processes .....	17
Chapter 4: Disk Diffusion Antimicrobial Susceptibility Testing Process .....	19
4.1 Reagents and Materials for Disk Diffusion Tests .....	21
4.2 Organism Growth for Inoculum and Testing Strains That Fail to Grow Satisfactorily .....	23
4.3 Preparing Inoculum for Disk Diffusion Tests.....	23
4.4 Inoculating the Test Plates.....	25
4.5 Applying Disks and Incubating Inoculated Agar Plates .....	25
4.6 Special Considerations for Fastidious Organisms .....	26
4.7 Reading Plates.....	28
4.8 Recording, Interpreting, and Reporting Results.....	29
4.9 Disk Diffusion Zone Diameter Equivalent Minimal Inhibitory Concentration Breakpoints .....	30
4.10 Disk Diffusion Method Limitations.....	30
Chapter 5: Broth Dilution Antimicrobial Susceptibility Testing Process .....	33
5.1 Reagents and Materials for Broth Dilution Tests.....	36
5.2 Organism Growth for Inoculum and Testing Strains That Fail to Grow Satisfactorily .....	40
5.3 Preparing Inoculum for Dilution Tests .....	41
5.4 Inoculum Preparation and Inoculation.....	42
5.5 Inoculum Suspension Colony Counts.....	44
5.6 Incubation .....	44
5.7 Special Considerations for Fastidious Organisms .....	44
5.8 Determining Broth Macro- or Microdilution End Points.....	46
5.9 Recording, Interpreting, and Reporting Results.....	49
5.10 Dilution Test Method Limitations .....	50
Chapter 6: Agar Dilution Antimicrobial Susceptibility Testing Process .....	53
6.1 Reagents and Materials for Agar Dilution Tests.....	56
6.2 Organism Growth for Inoculum and Testing Strains That Fail to Grow Satisfactorily .....	60
6.3 Preparing Inoculum for Dilution Tests .....	60
6.4 Inoculating Agar Plates.....	62

## Contents (Continued)

6.5	Incubating Agar Dilution Plates.....	62
6.6	Special Considerations for Fastidious Organisms .....	63
6.7	Determining Agar Dilution End Points.....	64
6.8	Recording, Interpreting, and Reporting Results.....	64
6.9	Dilution Test Method Limitations .....	65
Chapter 7:	Screening Tests to Detect Resistance.....	67
7.1	Screening Tests .....	67
7.2	Detecting Resistance in Staphylococci .....	67
7.3	Detecting Resistance in Enterococci.....	73
7.4	Detecting $\beta$ -Lactam Resistance in Gram-Negative Bacilli.....	74
7.5	Detecting Resistance in Streptococci.....	77
7.6	Detecting Penicillin Resistance and $\beta$ -Lactamase in <i>Haemophilus</i> spp. ....	78
Chapter 8:	Quality Control and Quality Assurance .....	79
8.1	Quality Control Purpose .....	79
8.2	Quality Control Responsibilities.....	79
8.3	Selecting Strains for Quality Control.....	80
8.4	Maintaining and Testing Quality Control Strains .....	82
8.5	Batch or Lot Quality Control .....	84
8.6	Acceptable Quality Control Ranges.....	85
8.7	Quality Control Testing Frequency .....	85
8.8	Out-of-Range Results With Quality Control Strains and Corrective Action.....	87
8.9	Reporting Patient Results When Out-of-Range Quality Control Results Are Observed .....	90
8.10	Confirming Results When Testing Patient Isolates .....	90
8.11	Reporting Minimal Inhibitory Concentration Results .....	91
8.12	End-Point Interpretation Control .....	91
Chapter 9:	Additional Antimicrobial Susceptibility and Resistance Reporting.....	93
9.1	Cumulative Antimicrobial Susceptibility Test Data Summary Reports .....	93
9.2	Veterinary Antimicrobial Resistance Monitoring Surveillance Programs.....	93
Chapter 10:	Conclusion.....	96
Chapter 11:	Supplemental Information .....	96
	References.....	97
	Appendix A. Preparation of Media, Supplements, and Reagents.....	100
	Appendix B. Conditions for Disk Diffusion Antimicrobial Susceptibility Tests .....	109
	Appendix C. Conditions for Broth and Agar Dilution Antimicrobial Susceptibility Tests ...	113
	Appendix D. Screening Test Methods to Detect Resistance.....	119
	Appendix E. Quality Control Strain Maintenance .....	122
	Appendix F. Antimicrobial Susceptibility Testing Quality Control Form .....	124
	Appendix G. Quality Control Protocol Flow Charts.....	126
	The Quality Management System Approach.....	130
	Related CLSI Reference Materials .....	132

## Foreword

In this revision of VET01, several sections were added or revised, as outlined in the Overview of Changes. One of the main updates is the reformatting of the standard to follow a laboratory's path of workflow, defined as the sequential processes of preexamination, examination, and postexamination. An overview of the antimicrobial susceptibility testing process is provided in the beginning of the standard in the new Figure 1 (see Chapter 3) and at the beginning of each method chapter (Chapters 4 through 6), with various testing methods shown in easy-to-follow step-action tables throughout the standard. Other improvements have been made in VET01 by incorporating relevant updates derived from CLSI documents M02<sup>2</sup> and M07<sup>3</sup> and by adding new antimicrobial agents or testing standards for veterinary pathogens.

The most current edition of CLSI document VET08<sup>1</sup> (formerly VET01S), a volume of tables published every 2 to 3 years, is made available with this standard to ensure users are aware of the latest Subcommittee on Veterinary Antimicrobial Susceptibility Testing (VAST) performance standards related to both methods and the information presented in the tables. Previously published tables should be replaced with the current editions for interpreting breakpoints. Because of potential international differences that restrict use of certain antimicrobial agents, some jurisdiction-specific restrictions are described in VET08<sup>1</sup> Table 1 footnotes and in VET08<sup>1</sup> Table 2A comments.

Significant changes in the revision of the VET08<sup>1</sup> tables since 2013 include veterinary-specific breakpoints for categorizing methicillin-susceptible and methicillin-resistant strains of *Staphylococcus pseudintermedius*, which are different from *Staphylococcus aureus* breakpoints. Newly approved antimicrobial agents, such as the fluoroquinolone pradofloxacin, the macrolides gamithromycin and tildipirosin, and the cephalosporin cefovecin have been added to VET08<sup>1</sup> using data presented by the sponsors. For testing of first-generation cephalosporins in dogs, cephalothin has been replaced with cephalexin, which is more predictive of susceptibility and is also used more commonly in dogs. These and other specific changes to the VET08<sup>1</sup> tables are summarized at the beginning of VET08.<sup>1</sup>

Other important additions to the VET08<sup>1</sup> tables are breakpoints for antimicrobial agents that did not previously have a veterinary-specific breakpoint. These are often human antimicrobial agents that are not approved in all countries for animals but may be used legally in some countries by veterinarians in their generic forms. The new additions include doxycycline (for dogs and horses), minocycline (for dogs), amikacin (for dogs and horses), cephalexin (for dogs), cefazolin (for dogs and horses), ampicillin/amoxicillin (for dogs, pigs, and horses), amoxicillin-clavulanate (for dogs and cats), and piperacillin-tazobactam (for dogs), among others. The veterinary diagnostic and related laboratory community is encouraged to provide feedback so that VET01 and its supplement VET08<sup>1</sup> can be kept up to date, maintaining clinical relevance.

Many other editorial and procedural changes in this edition of VET01 were made since 2013 following meetings of the Document Development Committee on Veterinary AST Methods Standard and the Subcommittee on VAST. The most important changes in this standard are summarized below.

## Overview of Changes

This standard replaces the previous edition of the approved standard, VET01-A4, published in 2013. Several changes were made in this edition, including:

- **General:**
  - To harmonize with the International Organization for Standardization, the terms for the methods for inoculum preparation have been changed. “Growth method” has been changed to “broth culture method,” and “direct colony suspension method” has been changed to “colony suspension method” throughout the standard.